Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zerun Bio Lands CEPI Grant to Start Trials of Multi-Variant COVID Vaccine

publication date: Feb 10, 2022

Shanghai Zerun Bio announced an additional $8 million grant from CEPI to conduct trials of its COVID-19 multi-variant vaccine candidate. CEPI, the Coalition for Epidemic Preparedness Innovations, formed a collaboration with Zerun that includes access to finished vaccines, which will be distributed by COVAX. The latest grant brings CEPI's total support of Zerun's COVID vaccines to $25 million. Zerun will conduct a Phase I/II trial of its prototype and multi-variant vaccine candidates in Mali to assess their safety and immunogenicity. Zerun is a subsidiary of Walvax Bio. More details....

Stock Symbol: (SHZ: 300142)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.